Rowan Chapman joined MDV in 2001. Through her relationships with industry and academic leaders advancing the fields of personalized medicine, drug discovery technology and regenerative medicine she both sources new life sciences investments and works to develop and grow MDV life sciences companies including Artemis Health, Pacific Biosciences, Adamas Pharmaceuticals and ParAllele BioScience (acquired by Affymetrix). Rowan is also a member of the Personalized Medicine Coalition.
Prior to joining MDV she held the position of director of business development at Rosetta Inpharmatics (acquired by Merck) where she established collaborative partnerships with organizations in the pharmaceutical, agricultural and biotech fields as well as among various research institutions. Previously, Rowan held the position of marketing manager at Incyte Genomics.
Rowan holds a Ph.D. in cellular and molecular biology from the MRC Laboratory of Molecular Biology in Cambridge University, United Kingdom, where she also earned a bachelor's degree with first class honors in Biochemistry. She served postdoctoral fellowships at the University of California, San Francisco, as well as at the MRC-Laboratory of Molecular Biology at Cambridge. Prior to her work in industry, she authored or co-authored more than a dozen articles and patents.
Board & Advisor Roles (3)Update
|Mar 5, 2015||Xconomy - GE Backs Evidation Health to Tackle Digital Health|
|Jan 7, 2013||Xconomy - Risa Stack Leaves Kleiner; Third Valley VC to Join GE|
|Feb 11, 2011||Xconomy - Fluidigm Completes IPO on 2nd Try, Geron CEO Exits, Amgen Pushes 'Son of Dmab,' & More Bay Area Life Sciences News|
|Feb 8, 2011||Xconomy - Computing in the Age of the $1,000 Genome: The Photo Gallery|
|Feb 7, 2011||Xconomy - Diagnostics Are Warming Up in Era of Fast, Cheap Sequencing, Says MDV's Rowan Chapman|
|Feb 7, 2011||Xconomy - See You This Afternoon at "Computing in the Age of the $1,000 Genome"|
|Dec 8, 2010||Xconomy - Sequenta raises 13000000 in venture round|